TrialThe oncologist2023

Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials.

Lee X Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.